for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Epigenomics AG

ECXn.DE

Latest Trade

0.43EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.32

 - 

3.20

As of on the Frankfurt Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
0.43
Open
--
Volume
--
3M AVG Volume
0.32
Today's High
--
Today's Low
--
52 Week High
3.20
52 Week Low
0.32
Shares Out (MIL)
47.13
Market Cap (MIL)
20.31
Forward P/E
-1.81
Dividend (Yield %)
--

Next Event

Epigenomics AG Extraordinary Shareholders Meeting

Latest Developments

More

Epigenomics 9-mth Adj. EBITDA At EUR -8.1 Mln

Epigenomics Plans Capital Reduction And To Issue Convertible Bonds

Epigenomics H1 Net Loss Narrows To EUR 6.4 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Epigenomics AG

Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.

Industry

Biotechnology & Drugs

Contact Info

Geneststrasse 5

10829

Germany

+49.30.243450

https://www.epigenomics.com/

Executive Leadership

Heino.N.F.M von Prondzynski

Chairman of the Supervisory Board

Jorge A. Garces

President, Chief Scientific Officer

Gregory Hamilton

Chief Executive Officer

Ann Clare Kessler

Vice Chairwoman of the Supervisory Board

Guenther Reiter

Vice Chairman of the Supervisory Board

Key Stats

2.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (EUR)

2017

-0.410

2018

-0.470

2019

-0.460

2020(E)

-0.240
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.80
Price To Book (MRQ)
3.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.42
LT Debt To Equity (MRQ)
9.36
Return on Investment (TTM)
-203.55
Return on Equity (TTM)
-147.93

Latest News

Latest News

BRIEF-Epigenomics Confirms Its 2020 Outlook

* EPIGENOMICS AG REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS

BRIEF-Epigenomics Sees 2020 Revenues Within Range Of EUR 1.0-2.0 Mln

* DGAP-NEWS: EPIGENOMICS AG REPORTS FINANCIAL RESULTS FOR FISCAL YEAR 2019 AND PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020

BRIEF-Epigenomics Implements Measures To Reduce Costs During COVID-19 Pandemic

* IMPLEMENTS COMPREHENSIVE MEASURES TO REDUCE COSTS DURING COVID-19 PANDEMIC CRISIS

BRIEF-Epigenomics Postpones AGM, Comments On Coronavirus Impact

* DGAP-NEWS: EPIGENOMICS ANNOUNCES POSTPONEMENT OF ANNUAL GENERAL MEETING DUE TO CORONAVIRUS AND PRELIMINARY 2019 FLASH FINANCIAL RESULTS

BRIEF-Epigenomics: Centers For Medicare & Medicaid Services Open NCD Review Process For Epi proColon

* SAID ON FRIDAY CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPENED NATIONAL COVERAGE DETERMINATION (NCD) REVIEW OF EPI PROCOLON, EPIGENOMICS' BLOOD TEST FOR COLORECTAL CANCER SCREENING

BRIEF-Epigenomics: Blood Test Shows Promise In The Detection Of Liver Cancer

* DGAP-NEWS: EPIGENOMICS AG: BLOOD TEST SHOWS PROMISE IN THE DETECTION OF LIVER CANCER

BRIEF-Epigenomics: Cumulative Loss Of More Than Half Of Nominal Share Capital

* NOTIFIES A CUMULATIVE LOSS OF MORE THAN HALF OF NOMINAL SHARE CAPITAL OF COMPANY HAS BEEN INCURRED

BRIEF-Epigenomics FY Net Loss Narrows To EUR 10.2 Million

* IN 2017, EPIGENOMICS' TOTAL REVENUE DECREASED TO EUR 1.9 MILLION (2016: EUR 4.2 MILLION)

BRIEF-Epigenomics Gets Ce-Ivd Mark For Lung Cancer Test Epi Prolung

* DGAP-NEWS: EPIGENOMICS AG GETS CE-IVD MARK FOR LUNG CANCER TEST EPI PROLUNG(R) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-‍Epigenomics announces recent payment decision by CMS​

* Epigenomics - CMS has changed pricing determination for Epi proColon(R), only fda-approved blood-based test for colorectal cancer (CRC) screening

BRIEF-Epigenomics Q3 EBITDA loss narrows to 2.0 million euros

* EPIGENOMICS AG ANNOUNCES 2017 THIRD QUARTER AND NINE MONTHS FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up